An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase.
What is known and objective: CC‐292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC‐292 tablet formulation (P22 tablet (P22‐TAB) and CC‐292 capsule formulati...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 47; no. 8; pp. 1186 - 1194 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Aug2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |